News Center
AI+ New Drug Development Platform InfiZhi Pharma Receives Pre-A Round Investment from Livzon Pharmaceutical
Release time:
2021-02-05
On February 5, 2021, Beijing Infinite Intelligence Pharma Co., Ltd. announced that it has received Pre-A round investment from Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd., a wholly-owned investment platform of Lizhu Pharmaceutical.
According to Infinite Intelligence Pharma, with the support of angel round investment from Zhongke Chuangxing and Zhongjinghe Group obtained in August 2019, the AI new drug development platform "Smart Drug Brain" developed by Infinite Intelligence Pharma has taken shape. This platform integrates cutting-edge artificial intelligence-driven drug design (AIDD) and next-generation computer-aided drug design (CADD) technologies, deeply covering the entire process from target discovery to preclinical candidate compounds. "Smart Drug Brain" accurately calculates and predicts the multidimensional properties of designed compounds, significantly enhancing the level of innovative drug research and development and the success rate of early-stage research and development, meeting the urgent demand for efficiency and speed in the pharmaceutical industry.
Dr. Pei Jianfeng, founder of Infinite Intelligence Pharmastated: "Currently, the development of the third wave of artificial intelligence technology is in full swing, significantly changing human lifestyles and the paradigm of scientific research and development. It is expected to achieve breakthroughs in the field of new drug development in the near future. Infinite Intelligence Pharma is committed to promoting the development of efficient and powerful AI + new drug research and development technologies and platforms, with the mission of reducing the overall average cost of new drug research and development in the global pharmaceutical industry to less than one-tenth of the original. This financing will be used to upgrade the team, improve the intelligent drug research and development system, and expand the research and development pipeline, better serving global pharmaceutical companies, biotechnology companies, and partners. Infinite Intelligence Pharma also looks forward to using this round of financing to achieve world-class breakthroughs in AI + new drug research and development technology and new drug research and development pipeline."
Dr. Liu Jianing, Chief Investment Officer of Lizhu Pharmaceuticalstated: "The global pharmaceutical industry urgently needs AI + new drug research and development companies that can truly understand the needs of drug research and development and design innovative pharmaceutical molecules with clinical advantages. We highly recognize the technical capabilities and research and development direction of the Infinite Intelligence Pharma team in the AI + new drug research and development platform. Infinite Intelligence Pharma has demonstrated a profound understanding of how AI can effectively empower new drug research and development and efficient execution in its early entrepreneurial stage. The developed research and development module system and algorithms are at the leading level in the international industry. Lizhu Pharmaceutical Group is very fortunate to find such a long-term partner to jointly solve the difficulties and pain points in new drug research and development."
About Beijing Infinite Intelligence Pharma Co., Ltd.
The Infinite Intelligence Pharma team brings together top domestic experts in drug design and artificial intelligence drug research, being one of the earliest internationally and the first domestically to apply cutting-edge AI technology to new drug development. In the past year and a half of development, Infinite Intelligence Pharma has transformed the successful technical experience accumulated by the team into an AI new drug research and development system with independent intellectual property rights—Smart Drug Brain (PharmaMind).
Smart Drug Brain is driven by data, experts, and technology, integrating expert intelligence, computational intelligence, perceptual intelligence, and cognitive intelligence. This system develops and integrates multiple underlying drug research and development tools for actual new drug research and development application scenarios, capable of adapting workflows based on actual business needs. The Smart Drug Brain platform includes globally leading practical core technologies such as "system-based target discovery and combination analysis," "prediction of potential drug resistance mutation sites for drug targets," "structure-based druggability analysis of proteins," "structure-based three-dimensional molecular generation," "high-precision ultra-high-throughput virtual screening," "high-drug-like lead compound optimization," "multi-target de novo design and optimization," "allosteric drug/IDP drug design," and "high-precision compound structure image recognition." In response to unmet clinical needs, relying on the Smart Drug Brain system, Infinite Intelligence Pharma is committed to promoting the development of new drug research and development pipelines that reflect the absolute advantages of AI technology. The progress of the current research and development pipeline is smooth and has achieved encouraging results.
About Lizhu Pharmaceutical Group Co., Ltd.
Lizhu Pharmaceutical (1513.HK, 000513.SZ) is a leading comprehensive pharmaceutical group in China that integrates research and development, production, and sales. Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd. is a wholly-owned investment platform established by Lizhu Pharmaceutical in Zhuhai Hengqin, dedicated to discovering and supporting leading pharmaceutical innovation technologies and product research and development in China.
About Zhongke Chuangxing
Zhongke Chuangxing is oriented towards investing in "hard technology" and established a medical investment team in 2017, mainly focusing on upstream research and development and production enterprises in the pharmaceutical and medical device industry chain. To date, it has participated in investments in more than 20 early-stage companies. The invested companies include: Keke Life, Bodong Medical, Wushuang Medical, Zhongke Weiguang, Chuan Shi Biological, Shenxin Biological, Zehui Biological, Lianxin Medical, etc. Zhongke Chuangxing Medical Investment has made positive explorations in the transformation of scientific research achievements in universities, with more than 10 invested companies incubated from the Chinese Academy of Sciences, Peking University, Tsinghua University, West Lake University, Shanghai Jiao Tong University, etc.
About Zhongjinghe Group
Zhongjinghe Group was established in 1993 and is one of the earliest global cross-border VC institutions to enter the Asia-Pacific region, focusing on investing in innovative projects at the forefront of global technology, actively promoting technological progress and the social application of technological achievements, and continuously creating value for society. Zhongjinghe Group continues to focus on three major investment directions: health care, enterprise intelligence, and sustainable development. It currently has offices in Silicon Valley, Beijing, and Taipei, with cumulative investments in over 400 companies, creating more than 100 successful cases of IPOs and mergers and acquisitions.
In the healthcare field, it focuses on innovative biopharmaceuticals, digital healthcare, medical devices, and medical services. It has invested in companies such as Aikang Guobin, Medtronic, Libang Instruments, and Lebertech, all of which have gone public. It has also invested in and laid out companies such as Boya Jiyin, SYNTHEGO, Kangsheng Global, Panorama Medicine, Infinite Intelligence Pharma, Engine Biosciences, DeepBiome, Kerry Corning, Rongxin Medical, Hengdao Pathology, Borui Kang, Anzhi Shengyi, Kemei Diagnostics, and many other excellent startups.
Related Information